Dextromethorphan/quinidine: Completed Phase II enrollment

Avanir completed enrollment of 220 patients in the double-blind, placebo-controlled, U.S. Phase II AVR-131 trial to evaluate 20/10 and 30/10 mg oral dextromethorphan/quinidine twice daily for 10 weeks. Top-line data are expected in late September or early October. Avanir said data from the trial will inform Phase III development of AVP-786 to treat agitation in AD patients. AVP-786 is a next generation compound containing deuterium modified dextromethorphan and ultra-low dose quinidine. AVP-786 is in Phase II testing to treat neuropathic pain and treatment-resistant depression. ...